Boone & The Labyrinth of Equity

by

The matter of Boone Capital’s recent acquisition of shares in HealthEquity, a firm dealing in the ephemeral realm of health-related financial arrangements, presents a curious case. One might consider it a ripple in the vast, indifferent ocean of capital, or perhaps a deliberate cartography of risk. According to the official records – those meticulously transcribed pronouncements emanating from the Securities and Exchange Commission – Boone Capital has secured 212,856 shares, representing a valuation of $19,499,738. A sum, one notes, that could fund a small, exquisitely curated library, or, more prosaically, a fleeting moment in the market’s capricious dance.

The fund’s investment, amounting to 6.12% of its $318.61 million U.S. equity portfolio as of December 31, 2025, is not, in itself, remarkable. The market, after all, is a labyrinth of such transactions, each echoing the others in an endless, recursive pattern. Consider, if you will, the holdings of Boone Capital, as revealed by these same official pronouncements:

  • NYSE: MDT: $41.19 million (13% of AUM)
  • NASDAQ: MIRM: $33.27 million (10.4% of AUM)
  • NASDAQ: IONS: $33.05 million (10.4% of AUM)
  • NASDAQ: CI: $26.55 million (8.3% of AUM)
  • NASDAQ: BMRN: $24.48 million (7.7% of AUM)

These figures, presented with the sterile precision of a surveyor’s map, offer little insight into the underlying rationale. One suspects, however, that the pursuit of profit, however veiled in the language of “value creation,” remains the dominant principle. As of February 17, 2026, HealthEquity’s share price stood at $74.36 – a figure diminished by 34.3% over the preceding year, and lagging behind the S&P 500 by a considerable margin. A performance, one might observe, that mirrors the inevitable entropy of all things.

A Brief Compendium Concerning HealthEquity

Metric Value
Price (as of market close 2/17/26) $74.36
Market Capitalization $6.43 billion
Revenue (TTM) $1.29 billion
Net Income (TTM) $191.83 million

HealthEquity, for the uninitiated, operates within the domain of cloud-based platforms for health savings accounts, flexible spending accounts, and health reimbursement arrangements. It is, in essence, a custodian of deferred gratification, a facilitator of financial transactions related to the unpredictable contingencies of human existence. The company’s clientele encompasses employers, benefits brokers, health plans, and individual consumers – a vast network of interconnected interests, each pursuing its own version of well-being.

The company’s recent performance, however, presents a more nuanced picture. The number of health savings accounts under its management grew by 7% year over year, reaching 10.6 million as of January 31, 2026. Sales for the third quarter rose to $322.2 million, up from $300.4 million in the previous year. Net income also experienced a significant increase, rising to $51.7 million compared to $5.7 million in the prior year. These figures, while encouraging, should not be mistaken for a harbinger of lasting prosperity. The market, as any seasoned observer will attest, is a fickle mistress, prone to sudden reversals and unforeseen calamities.

The decline in HealthEquity’s share price has, however, resulted in a lower forward price-to-earnings ratio of 17 – a level not seen in the past year. Whether this represents a genuine opportunity for investors remains to be seen. One is reminded of the apocryphal tale of the librarian who, upon discovering a rare and valuable manuscript, promptly used it to prop up a wobbly table. The pursuit of value, it seems, is often a matter of perspective.

Read More

2026-03-16 00:02